Применение ингаляций оксида азота при COVID-19

Ингаляционный оксид азота (iNO) благодаря своим свойствам оказывать противовирусное, антитромботическое и противовоспалительное действие, а также способности расширять кровеносные сосуды предлагается в качестве потенциального метода лечения COVID-19 (CoronaVIrusDisease 2019) и постковидного синдрома (ПКС). В настоящее время недостаточно ясными остаются вопросы селекции пациентов для лечения, а также подбора оптимальной дозировки iNO, продолжительности и времени его введения, а также способы его доставки. Эти факторы могут значительно повлиять на эффективность iNO-терапии.
Целью работы явились обсуждение физиологических основ использования iNO в лечении пациентов с COVID-19 и ПКС, анализ результатов проведенных исследований и демонстрация достижений в технике синтеза NO в медицине.
Заключение. Показано, что раннее назначение и использование высоких доз iNO представляется эффективным и безопасным методом лечения пациентов с COVID-19, поскольку направлено на основные патобиологические механизмы заболевания. iNO также может быть эффективен у пациентов с ПКС. Однако требуется дальнейшее изучение оптимального (непрерывного или прерывистого) режима дозирования. Последние достижения в области синтеза NO имеют большое значение для широкого практического применения терапии iNO.

1. Ignarro L.J. Nitric Oxide. Reference module in biomedical sciences. Elsevier; 2014. DOI: 10.1016/B978-0-12-801238-3.00245-2.

2. Nikolaidis A., Kramer R., Ostojic S. Nitric Oxide: the missing factor in COVID-19 severity? Med. Sci. (Basel). 2022; 10 (1): 3. DOI: 10.3390/medsci10010003.

3. Kapil V., Khambata R.S., Jones D.A. et al. The noncanonical pathway for in vivo nitric oxide generation: the nitrate-nitrite-nitric oxide pathway. Pharmacol. Rev. 2020; 72 (3): 692–766. DOI: 10.1124/pr.120.019240.

4. Гуманова Н. Оксид азота, его циркулирующие метаболиты NOx и их роль в функционировании человеческого организма и прогнозе риска сердечно-сосудистой смерти (часть I). Профилактическая медицина. 2021; 24 (9): 102–109. DOI: 10.17116/profmed202124091102. / Gumanova N. [Nitric oxide and its circulating NOx metabolites, their role in human body functioning and cardiovascular death risk prediction (part I).]. Profilakticheskaya meditsina. 2021; 24 (9): 102–109. DOI: 10.17116/profmed202124091102 (in Russian).

5. Lundberg J., Weitzberg E. Nasal nitric oxide in man. Thorax. 1999; 54 (10): 947–952. DOI: 10.1136/thx.54.10.947.

6. Bryan N.S., Lancaster J.R. Nitric oxide signaling in health and disease. In: Bryan N.S., Loscalzo J., eds. Nitrite and nitrate in human health and disease. Cham: Springer; 2017: 165–178. DOI: 10.1007/978-3-319-46189-2_23.

7. Meng H., Xiong R., He R. et al. CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. J. Infect. 2020; 81 (1): e33–39. DOI: 10.1016/j.jinf.2020.04.004.

8. Tzotzos S.J., Fischer B., Fischer H., Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit. Care. 2020; 24 (1): 516. DOI: 10.1186/s13054-020-03240-7.

9. Lan J., Ge J., Yu J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020; 581 (7807): 215–220. DOI: 10.1038/s41586-020-2180-5.

10. Ackermann M., Verleden S.E., Kuehnel M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 2020; 383 (2): 120–128. DOI: 10.1056/NEJMoa2015432.

11. Dominic P., Ahmad J., Bhandari R. et al. Decreased availability of nitric oxide and hydrogen sulfide is a hallmark of COVID-19. Redox Biol. 2021; 43: 101982. DOI: 10.1016/j.redox.2021.101982.

12. Montiel V., Lobysheva I., Gerard L. et al. Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. EBioMedicine. 2022; 77: 103893. DOI: 10.1016/j.ebiom.2022.103893.

13. Yu B., Ichinose F., Bloch D.B., Zapol W.M. Inhaled nitric oxide. Br. J. Pharmacol. 2019; 176 (2): 246–255. DOI: 10.1111/bph.14512.

14. Signori D., Magliocca A., Hayashida K. et al. Inhaled nitric oxide: role in the pathophysiology of cardio-cerebrovascular and respiratory diseases. Intensive Care Med. Exp. 2022; 10 (1): 28. DOI: 10.1186/s40635-022-00455-6.

15. Chen L., Liu P., Gao H. et al. Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin. Infect. Dis. 2004; 39 (10): 1531–1535. DOI: 10.1086/425357.

16. Keyaerts E., Vijgen L., Chen L. et al. Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound. Int. J. Infect. Dis. 2004; 8 (4): 223–226. DOI: 10.1016/j.ijid.2004.04.012.

17. Akerström S., Gunalan V., Keng C.T. et al. Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected. Virology. 2009; 395 (1): 1–9. DOI: 10.1016/j.virol.2009.09.007.

18. Siddiqi H.K., Mehra M.R. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J. Heart Lung Transplant. 2020; 39 (5): 405–407. DOI: 10.1016/j.healun.2020.03.012.

19. Tamminen P.J., Kerimov D.M., Viskari H. et al. Nasal nitric oxide is decreased in acute mild COVID-19 and related to viral load. J. Breath Res. 2022; 16 (4): 046003. DOI: 10.1088/1752-7163/ac7d6a.

20. Farsalinos K., Bagos P.G., Giannouchos T. et al. Smoking prevalence among hospitalized COVID-19 patients and its association with disease severity and mortality: an expanded re-analysis of a recent publication. Harm Reduct. J. 2021; 18 (1): 9. DOI: 10.1186/s12954-020-00437-5.

21. Tandon M., Wu W., Moore K. et al. SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: a randomized trial. Lancet Reg. Health Southeast Asia. 2022; 3: 100036. DOI: 10.1016/j.lansea.2022.100036.

22. Fakhr B.S., Di Fenza R., Gianni S. et al. Inhaled high dose nitric oxide is a safe and effective respiratory treatment in spontaneous breathing hospitalized patients with COVID-19 pneumonia. Nitric Oxide. 2021; 116: 7–13. DOI: 10.1016/j.niox.2021.08.003.

23. Parikh R., Wilson C., Weinberg J. et al. Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients. Ther. Adv. Respir. Dis. 2020; 14: 1753466620933510. DOI: 10.1177/1753466620933510.

24. Valsecchi C., Winterton D., Safaee Fakhr B. et al. High-dose inhaled nitric oxide for the treatment of spontaneously breathing pregnant patients with severe coronavirus disease 2019 (COVID-19) pneumonia. Obstet. Gynecol. 2022; 140 (2): 195–203. DOI: 10.1097/AOG.0000000000004847.

25. Zamanian R.T., Pollack Jr C.V., Gentile M.A. et al. Outpatient inhaled nitric oxide in a patient with vasoreactive idiopathic pulmonary arterial hypertension and COVID-19 infection. Am. J. Respir. Crit. Care Med. 2020; 202 (1): 130–132. DOI: 10.1164/rccm.202004-0937LE.

26. Ichinose F., Roberts Jr J.D., Zapol W.M. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation. 2004; 109 (25): 3106–3111. DOI: 10.1161/01.CIR.0000134595.80170.62.

27. Steudel W., Hurford W.E., Zapol W.M. et al. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology. 1999; 91 (4): 1090–1121. DOI: 10.1097/00000542-199910000-00030.

28. Taylor R.W., Zimmerman J.L., Dellinger R.P. et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA. 2004; 291 (13): 1603–1609. DOI: 10.1001/jama.291.13.1603.

29. Gebistorf F., Karam O., Wetterslev J., Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst. Rev. 2016 (6): CD002787. DOI: 10.1002/14651858.cd002787.pub3.

30. Prakash A., Kaur S., Kaur C. et al. Efficacy and safety of inhaled nitric oxide in the treatment of severe/critical COVID-19 patients: a systematic review. Indian J. Pharmacol. 2021; 53 (3): 236–243. DOI: 10.4103/ijp.ijp_382_21.

31. Beitler J.R., Thompson B.T., Baron R.M. et al. Advancing precision medicine for acute respiratory distress syndrome. Lancet Respir. Med. 2021; 10 (1): 107–120. DOI: 10.1016/S2213-2600(21)00157-0.

32. Tavazzi G., Pozzi M., Mongodi S. et al. Inhaled nitric oxide in patients admitted to intensive care unit with COVID-19 pneumonia. Crit. Care. 2020; 24 (1): 508. DOI: 10.1186/s13054-020-03222-9.

33. Garfield B., McFadyen C., Briar C. et al. Potential for personalised application of inhaled nitric oxide in COVID-19 pneumonia. Br. J. Anaesth. 2021; 126 (2): e72–75. DOI: 10.1016/j.bja.2020.11.006.

34. DeGrado J.R., Szumita P.M., Schuler B.R. et al. Evaluation of the efficacy and safety of inhaled epoprostenol and inhaled nitric oxide for refractory hypoxemia in patients with coronavirus disease 2019. Crit. Care Explor. 2020; 2 (10): e0259. DOI: 10.1097/CCE.0000000000000259.

35. Davis H.E., McCorkell L., Vogel J.M. et al. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023; 21 (3): 1–14. DOI: 10.1038/s41579-022-00846-2.

36. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October, 2021. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 [Accessed: May 01, 2023].

37. Wang J., Mei F., Bai L. et al. Serum nitrite and nitrate: a potential biomarker for post-covid-19 complications? Free Radic. Biol. Med. 2021; 175: 216–225. DOI: 10.1016/j.freeradbiomed.2021.08.237.

38. Muangritdech N., Hamlin M.J., Sawanyawisuth K. et al. Hypoxic training improves blood pressure, nitric oxide and hypoxia-inducible factor-1 alpha in hypertensive patients. Eur. J. Appl. Physiol. 2020; 120 (8): 1815–1826. DOI: 10.1007/s00421-020-04410-9.

39. ClinicalTrials.gov. Hypoxic-hyperoxic training in patients with cardiovascular pathology after COVID-19 infection. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT05379608 [Accessed: May 01, 2023].

40. Шейко Г., Исраелян Ю., Белова А. и др. Физиотерапевтические методы в реабилитации пациентов с COVID-19. Вестник физиотерапии и курортологии. 2020; 26 (4): 63–70. Доступно на: https://cyberleninka.ru/article/n/fizioterapevticheskie-metody-v-reabilitatsii-patsientov-s-covid-19?ysclid=ls0ayev7hg948878945 / Shejko G., Israeljan Ju., Belova A. et al. [Physiotherapeutic methods in the rehabilitation of patients with COVID-19]. Vestnik fizioterapii i kurortologii. 2020; 26 (4): 63–70. Available at: https://cyberleninka.ru/article/n/fizioterapevticheskie-metody-v-reabilitatsii-patsientov-s-covid-19?ysclid=ls0ayev7hg948878945 (in Russian).

41. Garnacho-Castaño M.V., Sánchez-Nuño S., Molina-Raya L. et al. Circulating nitrate-nitrite reduces oxygen uptake for improving resistance exercise performance after rest time in well-trained CrossFit athletes. Sci. Rep. 2022; 12 (1): 9671. DOI: 10.1038/s41598-022-13786-x.

42. Nelin L.D., Potenziano J.L. Inhaled nitric oxide for neonates with persistent pulmonary hypertension of the newborn in the CINRGI study: time to treatment response. BMC Pediatr. 2019; 19 (1): 17. DOI: 10.1186/s12887-018-1368-4.

43. Abou-Arab O., Huette P., Debouvries F. et al. Inhaled nitric oxide for critically ill COVID-19 patients: a prospective study. Crit. Care. 2020; 24 (1): 645. DOI: 10.1186/s13054-020-03371-x.

44. Chandel A., Patolia S., Ahmad K. et al. Inhaled nitric oxide via high-flow nasal cannula in patients with acute respiratory failure related to COVID-19. Clin. Med. Insights Circ. Respir. Pulm. Med. 2021; 15: 11795484211047065. DOI: 10.1177/11795484211047065.

45. Herranz L., da Silveira J.G., Trocado L.F.L. et al. Inhaled nitric oxide in patients with severe COVID-19 infection at intensive care unit – a cross sectional study. J. Crit. Care Med. (Targu Mures). 2021; 7 (4): 318–319. DOI: 10.2478/jccm-2021-0033.

46. Robba C., Ball L., Battaglini D. et al. Early effects of ventilatory rescue therapies on systemic and cerebral oxygenation in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome: a prospective observational study. Crit. Care. 2021; 25 (1): 111. DOI: 10.1186/s13054-021-03537-1.

47. Lotz C., Muellenbach R.M., Meybohm P. et al. Effects of inhaled nitric oxide in COVID‐19-induced ARDS – is it worthwhile? Acta Anaesthesiol. Scand. 2021; 65 (5): 629–632. DOI: 10.1111/aas.13757.

48. Roberts Jr J., Polaner D.M., Zapol W. et al. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992; 340 (8823): 818–819. DOI: 10.1016/0140-6736(92)92686-a.

49. Miller C., Miller M., McMullin B. et al. A phase I clinical study of inhaled nitric oxide in healthy adults. J. Cyst. Fibros. 2012; 11 (4): 324–331. DOI: 10.1016/j.jcf.2012.01.003.

50. Fakhr B.S., Wiegand S.B., Pinciroli R. et al. High concentrations of nitric oxide inhalation therapy in pregnant patients with severe coronavirus disease 2019 (COVID-19). Obstet Gynecol. 2020; 136 (6): 1109–1113. DOI: 10.1097/AOG.0000000000004128.

51. Каменщиков Н., Кузнецов М., Дьякова М. и др. Ингаляционная терапия коморбидного пациента с COVID-19 высокими дозами оксида азота: клинический случай. Сибирский журнал клинической и экспериментальной медицины. 2022; 37 (4): 180–187. DOI: 10.29001/2073-8552-2022-37-4-180-187. / Kamenshhikov N., Kuznecov M., D'jakova M. et al. [Inhalation therapy of a comorbid patient with COVID-19 with high doses of nitric oxide: a clinical case]. Sibirskiy zhurnal klinicheskoy i eksperimental'noy meditsiny. 2022; 37 (4): 180–187. DOI: 10.29001/2073-8552-2022-37-4-180-187 (in Russian).

52. Gerlach H., Keh D., Semmerow A. et al. Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study. Am. J. Respir. Crit. Care Med. 2003; 167 (7): 1008–1015. DOI: 10.1164/rccm.2108121.

53. Kamenshchikov N.O., Berra L., Carroll R.W. Therapeutic effects of inhaled nitric oxide therapy in COVID-19 patients. Biomedicines. 2022; 10 (2): 369. DOI: 10.3390/biomedicines10020369.

54. Ziehr D.R., Alladina J., Wolf M.E. et al. Respiratory physiology of prone positioning with and without inhaled nitric oxide across the coronavirus disease 2019 acute respiratory distress syndrome severity spectrum. Crit. Care Explor. 2021; 3 (6): e0471. DOI: 10.1097/CCE.0000000000000471.

55. Pierce C., Peters M., Cohen G. et al. Cost of nitric oxide is exorbitant. BMJ. 2002; 325 (7359): 336. DOI: 10.1136/bmj.325.7359.336.

56. Tzanetos D.R.T., Housley J.J., Barr F.E. et al. Implementation of an inhaled nitric oxide protocol decreases direct cost associated with its use. Respir. Care. 2015; 60 (5): 644–650. DOI: 10.4187/respcare.03308.